Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ImmunoCellular Therapeutics, Ltd.Financial_Report.xls
EX-31 - EX-31.2 - ImmunoCellular Therapeutics, Ltd.imuc-ex31_2014063052.htm
EX-31 - EX-31.1 - ImmunoCellular Therapeutics, Ltd.imuc-ex31_2014063051.htm
EX-32 - EX-32.2 - ImmunoCellular Therapeutics, Ltd.imuc-ex32_2014063054.htm
10-Q - 10-Q - ImmunoCellular Therapeutics, Ltd.imuc-10q_20140630.htm

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to the requirement set forth in Rule 13a -14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:

1.

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2014 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date:  August 8, 2014

By:

/s/ Andrew Gengos 

 

 

Name:

Andrew Gengos

 

 

Title:

President and Chief Executive Officer